Tag: Roszet

Roszet

Regulatory/FDA

OPDP: Risk, Efficacy Claims for Cholesterol Drug in Doctor Promotion Are False/Misleading

OPDP: Risk, Efficacy Claims for Cholesterol Drug in Doctor Promotion Are False/Misleading

June 27, 2022 – False or misleading claims and representations in a professional promotion about the efficacy and risks of a prescription drug for high cholesterol are cited in a June 2 Untitled Letter from the Food and Drug Administration’s (FDA’s) Office of Prescription Drug Promotion (OPDP) to Althera Pharmaceuticals LLC. OPDP reviewed a “Doctor […]

Read more